tbuckley/cabot-search huggingface dataset:
GPs won’t face higher indemnity costs, minister pledges
Authors: Adrian O’Dowd
Journal: BMJ (2017)

GPs will not have to pay any more for indemnity cover as a result of recent changes to compensation payments for patients who have had life changing injuries, MPs have been told.

David Mowat, community health and care minister, told a debate at Westminster Hall that GPs would not be worse off after the changes to the discount rate, announced in February by the UK justice secretary, Liz Truss. Mowat said that the NHS spends between £1.5bn (€1.7bn; $1.8bn) and £2bn a year on legal costs and indemnity costs, describing this as “a massive slug of money.”

However, he added, “The position of the government is that doctors will not have to pay …
NOVEL UTILIZATION OF DAPT SCORE AS A PREDICTOR OF LONG-TERM CLINICAL OUTCOMES IN HEMODIALYSIS PATIENTS ON PROLONGED DUAL ANTIPLATELET THERAPY AFTER CORONARY INTERVENTION
Authors: Tanaka Kazuki, Kentaro Jujo, Hisao Otsuki, Kensuke Shimazaki, Masashi Nakao, Hiroyuki Arashi, Junichi Yamaguchi, Nobuhisa Hagiwara
Journal: Journal of the American College of Cardiology (2017)
Prior estrogen therapy as a predictor of response to subsequent estramustine-based therapy in androgen-independent prostate cancer patients
Authors: J. A. Garcia, V. Weinberg, B. I. Rini, J. E. Rosenberg, C. J. Ryan, E. J. Small
Journal: Journal of Clinical Oncology (2004)

4595 Background: Secondary hormonal therapy with estrogens results in PSA responses in 30–60% of androgen-independent prostate cancer (AiPCa) patients. Diethylstilbestrol (DES) and other estrogens share a similar chemical structure with estramustine phosphate, which is commonly used together with taxanes as chemotherapy for AiPCa patients. It is unknown if prior estrogen therapy impacts on subsequent responses to estramustine-based chemotherapy. Methods: A retrospective chart review of 76 consecutive AiPCa patients who received secondary hormonal therapy with estrogens (DES or PC-SPES) was conducted. Patients who went on to receive estramustine-based chemotherapy were identified and their medical records abstracted. PSA response proportions (using Consensus Criteria), duration of response and overall survival was calculated. Results: Between 1998 and 2003, 76 AiPCa patients were treated with an estrogen (DES or PC-SPES). 48/76 (63%) had a PSA response. Of these, 24 subsequently were treated with estramustine-based chemotherapy. All but 1 had failed to respond to estrogen or developed progressive disease while on estrogen. 23/24 (96%) had metastatic disease. Median PSA was 69.1ng/mL. A PSA response to estramustine-based chemotherapy was observed in 13/23 (57%; CI = 34%–77%). Prior response to DES or PC SPES did not predict the likelihood of subsequent response to estramustine-based therapy (63% response rate in prior estrogen responders, 53% response rate in prior estrogen non-responders, p = 0.67). Conclusions: The use of prior estrogen therapy in AiPCa patients does not have an obvious impact on the likelihood of subsequent response to estramustine-based therapy, with 57% of patients responding to estramustine-based therapy following estrogen therapy. Prior response to estrogen was not predictive of response to estramustine-based therapy. These data suggest that estrogen and estramustine have different mechanisms of action, and that prior estrogen therapy need not exclude AiPCa patients from estramustine-based regimens. No significant financial relationships to disclose.
Phase II study of synthadotin (SYN-D; ILX651) administered daily for 5 consecutive days once every 3 weeks (qdx5q3w) in patients (Pts) with inoperable locally advanced or metastatic melanoma
Authors: S. Ebbinghaus, E. Hersh, C. C. Cunningham, S. O'Day, D. McDermott, J. Stephenson, D. A. Richards, J. Eckardt, O. L. Haider, L. A. Hammond
Journal: Journal of Clinical Oncology (2004)

7530 Background: SYN-D is a pentapeptide with a unique mechanism of action that potentially differs from microtubule stabilizers (taxanes and epothilones) and tubulin inhibitors (vinca alkaloids and other dolastatins) as it is postulated to inhibit microtubule nucleation. SYN-D has been chemically modified to improve pharmacological properties and is orally bioavailable with a therapeutic window potentially enhanced over previous generations of dolastatins. The substantial cardiovascular toxicity observed with previous dolastatins was not observed in the SYN-D phase I studies. Due to activity in melanoma observed both in xenograft models and in the phase I setting (Ebbinghaus, ASCO 2003), SYN-D is being evaluated in pts with locally advanced or metastatic melanoma. Methods: In this multi-institutional phase II study, SYN-D was administered at 28 mg/m2 IV for 30 mins qdx5q3w with response rate as the primary endpoint. The study was designed: to assess the feasibility of increasing SYN-D dose if <3/10 DLTs were observed during cycle 1 in the first 10 pts; with an early stopping rule after accrual of 25 pts in the event of no response. Pharmacokinetic blood draws were performed in cycle 1. Eligibility criteria: ECOG PS 0–1; no prior systemic chemotherapy; no active ocular melanoma; adequate organ function. Results: To date 20 pts have been treated; data on the first 15 as follows: M/F=10/5; age 30–75 (median 56); ECOG 0/1=11/4; treatment naïve/prior biologics=10/5; number of courses 24 (median 2). In the first 10 pts grade 3 or 4 non-dose-limiting, predictable (day 15), and self-limited neutropenia was seen in 2 (20%) and 3 (30%) pts, respectively. Other toxicities were grade1–2: alopecia (n=4); fatigue (n=3); and nausea/vomiting (n=3). To date, no sensory neuropathy, thrombocytopenia, anemia or cardiovascular toxicity has been observed. Due to lack of DLT in the first 10 pts, the dose of SYN-D was escalated to 34 mg/m2 in subsequent pts. Assessment of response is in progress. Conclusion: SYN-D is a safe, well-tolerated treatment in locally advanced and metastatic melanoma pts. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration ILEX Products, Inc., an affiliate of ILEX Oncology ILEX Products, Inc., an affiliate of ILEX Oncology ILEX Oncology, Inc. ILEX Products, Inc., an affiliate of ILEX Oncology ILEX, Inc ILEX Products, Inc., an affiliate of ILEX Oncology ILEX Products, Inc., an affiliate of ILEX Oncology
Blood Clotting and Allied Problems:
Journal: Annals of Internal Medicine (1950)

Here is the first of a series of reports by groups of outstanding investigators in specified fields which are sure to become indispensable aids to true students of medicine. The careful selection of the contributors and the fundamental nature of their presentation will appeal to those readers who are seeking authentic, practical information. For instance, "Blood Clotting and Hemostasis" is presented by L. B. Jaques, of Canada, "Fibrinolytic Enzymes" by Tage Astrup of Copenhagen, "Initiation and Acceleration Factors in Thrombosis" by K. M. Brinkhaus, "Protein Equilibrium Reactions in the Blood-Clotting Mechanism" by W. H. Seegers and A. G. Ware and "Dicoumarol and the Estimation of Prothrombin" by Karl Link, and there are others of equal importance. The discussion of the papers by the other members of the group adds great interest and clarification. In an extensive appendix the exact procedures for prothrombin determinations which are carried out in the various
Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR+) metastatic breast cancer (MBC).
Authors: Antoinette R. Tan, Serena Tsan-Lai Wong, Robert D. Warren, Jennifer Eng-Wong, Minetta C. Liu, Amelia Bruce Zelnak, Yong Lin, Weichung Shih, Shridar Ganesan, Generosa Grana, Claudine Isaacs, Deborah Toppmeyer
Journal: Journal of Clinical Oncology (2014)

531 Background: Preclinical studies show that addition of an antiangiogenesis agent improves efficacy of aromatase inhibition in hormone-sensitive breast cancer. Sorafenib is a multitargeted kinase inhibitor of VEGFRs, PDGFRs, FLT3, c-kit, and RAF. In this phase I/II multicenter study, the addition of sorafenib to letrozole as first-line therapy of HR+ MBC was evaluated. We previously reported the phase II dose to be letrozole 2.5 mg daily with sorafenib 400 mg BID. Methods: Eligible patients (pts) were postmenopausal, had measurable or evaluable HR+ MBC, and no prior therapy for metastases. Prior adjuvant tamoxifen (TAM) or aromatase inhibitor (AI) was allowed. The primary endpoint was clinical benefit rate (CBR= PR + SD ≥ 6 mo). The trial planned to enroll 58 pts to detect a CBR of ≥ 67% in a single-stage phase II design (80% power, α = .05). Secondary endpoints were progression-free survival (PFS) and overall survival (OS). Results: 54 pts (median age 54 yrs, range 21-84; median ECOG PS 0, range 0-2) were treated (13 pts in phase I) between 8/2008 – 12/2012 at which time the study closed due to slow accrual. 44% had de novo MBC, 39% pts had prior adjuvant TAM, 11% had prior adjuvant AI, and 2% had both prior TAM and AI. Median no. of cycles was 9 (range 1-62). The median daily dose of sorafenib was 400 mg. Most common gr 1-3 toxicities (%) were hand-foot skin (HFS) reaction (35%), hypertension (33%), rash (26%), diarrhea (19%), joint pains (15%), fatigue (13%), and alopecia (13%). 3 pts had HFS reaction that led to discontinuation of therapy. 5 pts had grade 2-3 rash that led to dose interruption. Of 41 pts evaluable for response, 39% (16 pts) had PRs and 41% (17 pts) had SD ≥ 6 mo. The CBR was 80.5% (95% CI: 65.1 - 90.9%). Median PFS was 20.2 mo (95% CI: 12.4 - 54.5 mo) and median OS was 51.5 mo (lower 95% CI: 44.7 mo). 11 pts continue on study with a median duration of 26 mo (range 14 – 60) and the median daily dose of sorafenib for these pts is also 400 mg. Conclusions: Letrozole combined with sorafenib was active in the treatment of HR+ MBC, and produced durable clinical benefit in a subset of pts as first-line therapy. Treatment benefit was still observed in pts who received lower than the recommended daily dose of sorafenib. Clinical trial information: NCT00634634.
MYOCARDIAL SCAR BUT NOT ISCHEMIA PREDICTS DEFIBRILLATOR SHOCKS AND SUDDEN CARDIAC DEATH IN PATIENTS WITH REDUCED LEFT VENTRICULAR EJECTION FRACTION
Authors: Ankur Gupta, Meagan Harrington, Navkaranbir Bajaj, Christine Albert, Jon Hainer, Victoria Morgan, Courtney Foster, Paco Bravo, Sara Seidelmann, Tomas Vita, Thomas Christensen, Sharmila Dorbala, Ron Blankstein, Viviany Taqueti, William Stevenson, Marcelo F. Di Carli
Journal: Journal of the American College of Cardiology (2017)
Serum S-100B protein is a strong independent prognostic marker for distant-metastasis free survival (DMFS) in stage III melanoma patients: An evaluation of the EORTC randomized trial 18952 comparing IFNα versus observation
Authors: S. Suciu, G. Ghanem, W. Kruit, K. Stoitchkov, P. Patel, M. Delaunay, T. ten Hagen, E. Musat, F. Salès, A. M. Eggermont
Journal: Journal of Clinical Oncology (2007)

8518 Background: S100B serum levels have been reported to correlate with tumor stage and outcome, especially in metastatic melanoma. In the EORTC 18952 randomized trial assessing the value of intermediate doses (10 MU or 5 MU) of IFNa vs Observation, a side study on S100B has been set-up in order to assess 1) the prognostic importance of initial measurement of S100B; 2) the risk of developing distant metastases in patients with a S100B≥0.2 μg/l; 3) the prognostic importance of the latest measurement of S100B level on the subsequent outcome. Methods: The serial measurements of S100B, made by immunoluminometric assay LIA-mat (Sangtec Medical, Sweden) have been performed at randomization in 18952 study, at end of 4-week IFNa induction/observation, and thereafter, at month 1, 3, 6, 9, 12, 16, 20, 24, 30 and 36. The prognostic impact regarding DMFS of the latest value of S100B was assessed via the Cox time-dependent model. Results: A total of 211 patients, stage IIb (N=51) or stage III (N=160), were randomized in the 18952 study between 1996 and 2000, had their initial serum S100B protein level assessed: in 178 patients (84%) S100B was &lt;0.2 μg/l and in 33 (16%) it was ≥0.2 μg/l. The 6-month DMFS rate was 90% (SE=2%) vs 70% (SE=8%) and the 1-year rate was 76% (SE=3%) vs 49% (SE=9%). The cumulative rate of developing metastases after the first assessment of S100B ≥0.2 μg/l (N=88) was 15% at 2 months, 45% at 6 months and 55% at 1 year. Using the Cox Time dependent model for DMFS, the estimated hazard ratio (HR) for those with the latest measurement S100B(t)≥0.2 μg/l vs S100B(t)&lt;0.2 μg/l was 3.7 (95% CI 2.6–5.3), P&lt;0.0001, in univariate analysis, and HR=4.4 (P&lt;0.0001) when adjusted for the number of positive lymph nodes (HR=1.82, P&lt;0.0001). The HR was 6.8 in stage III patients and 1.3 in stage IIb. In stage III, no treatment differences (IFNa vs Observation) were observed regarding DMFS and time to S100B≥0.2 μg/l. Conclusions: In stage III melanoma patients S100B protein is a strong prognostic marker regarding DMFS and probably S100B might be used as a surrogate endpoint for DMFS, but this requires further investigations (e.g. in EORTC 18991). In stage IIb, its prognostic importance was far lower. [Table: see text]
WORSENING TRICUSPID REGURGITATION AND INCREASED MORTALITY AFTER AORTIC VALVE REPLACEMENT: INSIGHTS FROM PARTNER2A
Authors: Paul Cremer, L. Leonardo Rodriguez, Yiran Zhang, Maria Alu, Brian Lindman, Alan Zajarias, Rebecca Hahn, Stamatios Lerakis, S. Chris Malaisrie, Pamela Douglas, Philippe Pibarot, Lars Svensson, Martin Leon, Wael Jaber
Journal: Journal of the American College of Cardiology (2017)
Targeting the PI3K signaling cascade in <i>PIK3CA</i> mutated endometrial cancer in a primary human xenograft model.
Authors: Leslie Siriya Bradford, Jose Alejandro Rauh-Hain, Rachel Marie Clark, Jolijn W Groeneweg, Ling Zhang, Celeste M DiGloria, Darrell R. Borger, Whitfield Board Growdon, John O. Schorge, Rosemary Foster, Bo R Rueda
Journal: Journal of Clinical Oncology (2013)

e13564 Background: Alterations in the PI3K pathway are highly prevalent in endometrial cancer due to PIK3CA mutation and loss of PTEN. Given these data, we investigated the anti-tumor activity of the PI3K inhibitor NVP-BKM120 (BKM) as a single agent and in combination with standard cytotoxic chemotherapy in a human primary endometrial xenograft model. Methods: NOD/SCID mice bearing xenografts of primary human tumors with and without PIK3CA gene mutations were randomly divided into two- and four-arm cohorts with equivalent tumor volumes. Three single agent experiments tested the effectiveness of NVP-BKM120 against two endometrioid (PIK3CA wild type and H1047L mutant) and one carcinosarcoma (PIK3CA R88Q mutant) endometrial cancer. Three four arm experiments tested NVP-BKM120 alone and in combination with paclitaxel and carboplatin (P/C) in two endometrioid tumors (both R88Q) and one carcinosarcoma (no PIK3CA mutation detected). Following in vivo study, tumors from the NVP-BKM120 , P/C, P/C+ NVP-BKM120 and vehicle treated mice were processed for determination of PI3K/AKT/mTOR pathway activation. Wilcoxan rank sum analysis was utilized to compare tumor growth across all treatment experiments. Results: In endometrioid single agent experiments, NVP-BKM120 resulted in tumor growth suppression starting at days 5-10 compared to the linear growth observed in vehicle treated tumors (p&lt;0.04 in all experiments). In all experiments, tumor resurgence manifested between days 14-25 (p&lt;0.03). When combined with P/C, the NVP-BKM120 resistance pattern failed to develop in all three xenograft lines (p&lt;0.05) while synergistic tumor growth suppression (p&lt; 0.05) of only one xenograft tumor harboring the R88Q mutation was observed. Acute treatment with NVP-BKM120 led to a decrease in pAKT, whereas, there was no difference in pAKT levels following chronic therapy compared to vehicle. Conclusions: These data suggest that NVP-BKM120 mediated inhibition of the PI3K pathway in endometrial tumors with and without a PIK3CA mutation precludes tumor growth in a primary xenograft model. While a pattern of resistance emerges, this effect appears to be mitigated by the addition of conventional cytotoxic chemotherapy.
THE PREVALENCE AND DISTRIBUTION OF VENTRICULAR ARRHYTHMIAS PRIOR TO VENTRICULAR ASSIST DEVICE IMPLANTATION: A THIRTEEN YEAR INSTITUTIONAL EXPERIENCE
Authors: Deep Pujara, Brian Greet, David Burkland, Mark Pollet, Deepthi Sudhakar, Francia Rojas, Briana Costello, Alexander Postalian, Zachary Hale, Ben Jenny, Carol Lai, Kenneth Igbalode, Divesh Wadhera, Masahiro Ono, Jeffrey Morgan, Leo Simpson, Andrew Civitello, Jie Cheng, Nilesh Mathuria
Journal: Journal of the American College of Cardiology (2017)
RISK OF ADVERSE OUTCOMES IN TREATMENT MODALITIES FOR SEVERE AORTIC STENOSIS IN RANDOMIZED CONTROL TRIALS: DIRECT AND INDIRECT COMPARISONS
Authors: Navkaranbir S. Bajaj, Garima Arora, Nirav Patel, Rajat Kalra, Shikhar Vohra, Amier Ahmad, Pankaj Arora
Journal: Journal of the American College of Cardiology (2017)
HANDS DOWN: OPERATOR HAND VERSUS TORSO RADIATION EXPOSURE DURING TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Alec Vishnevsky, Rady Ho, Michael Savage, David Fischman, Praveen Mehrotra, John C. Entwhistle, Jordan Goldhammer, Rebecca Marcantuono, Lisa Moss, John Keklak, Marguerite Davis, Theresa Schmitz, Paul Walinsky, Rohinton Morris, Nicholas Ruggiero
Journal: Journal of the American College of Cardiology (2017)
Vitamin A–coupled liposomes containing siRNA against HSP47 ameliorate skin fibrosis in chronic graft-versus-host disease
Authors: Tomohiro Yamakawa, Hiroyuki Ohigashi, Daigo Hashimoto, Eiko Hayase, Shuichiro Takahashi, Miyono Miyazaki, Kenjiro Minomi, Masahiro Onozawa, Yoshiro Niitsu, Takanori Teshima
Journal: Blood (2018)

Key Points HSP47+ myofibroblasts are accumulated in the fibrotic lesions of chronic GVHD and promote fibrosis in a CSF-1R+ macrophage-dependent manner. Vitamin A–coupled liposomes containing HSP47 siRNA abrogate HSP47 expression in myofibroblasts and ameliorate fibrosis in chronic GVHD.
IMPROVEMENT IN LDL IS ASSOCIATED WITH DECREASE IN NON-CALCIFIED PLAQUE VOLUME ON CTA AS MEASURED BY AUTOMATED QUANTITATIVE SOFTWARE
Authors: Balaji Tamarappoo, Yuka Otaki, Mhairi Doris, Yoav Arnson, Heidi Gransar, Sean Hayes, John Friedman, Louise Thomson, Frances Wang, Alan Rozanski, Piotr Slomka, Damini Dey, Daniel Berman
Journal: Journal of the American College of Cardiology (2017)
Treatment of Graft Failure with Fludarabine (Flu), Antithymocyte Globulin (ATG) and a Second Allogeneic Stem Cell Transplantation (SCT).
Authors: Elias J. Jabbour, Munir Shahjahan, Gabriela Rondon, Paolo Anderlini, Sergio Giralt, Daniel R. Couriel, Richard E. Champlin, Issa F. Khouri
Journal: Blood (2005)
Semantics in active surveillance for men with localized prostate cancer — results of a modified Delphi consensus procedure
Authors: Sophie M. Bruinsma, Monique J. Roobol, Peter R. Carroll, Laurence Klotz, Tom Pickles, Caroline M. Moore, Vincent J. Gnanapragasam, Arnauld Villers, Antti Rannikko, Riccardo Valdagni, Mark Frydenberg, Yoshiyuki Kakehi, Christopher P. Filson, Chris H. Bangma
Journal: Nature Reviews Urology (2017)

Active surveillance (AS) is broadly described as a management option for men with low-risk prostate cancer, but semantic heterogeneity exists in both the literature and in guidelines. To address this issue, a panel of leading prostate cancer specialists in the field of AS participated in a consensus-forming project using a modified Delphi method to reach international consensus on definitions of terms related to this management option. An iterative three-round sequence of online questionnaires designed to address 61 individual items was completed by each panel member. Consensus was considered to be reached if ≥70% of the experts agreed on a definition. To facilitate a common understanding among all experts involved and resolve potential ambiguities, a face-to-face consensus meeting was held between Delphi survey rounds two and three. Convenience sampling was used to construct the panel of experts. In total, 12 experts from Australia, France, Finland, Italy, the Netherlands, Japan, the UK, Canada and the USA participated. By the end of the Delphi process, formal consensus was achieved for 100% (n = 61) of the terms and a glossary was then developed. Agreement between international experts has been reached on relevant terms and subsequent definitions regarding AS for patients with localized prostate cancer. This standard terminology could support multidisciplinary communication, reduce the extent of variations in clinical practice and optimize clinical decision making.
UTILIDAD DE LA VISIÓN POR COMPUTADOR PARA LA DETECCIÓN DE PÓLIPOS PEQUEÑOS Y PLANOS
Authors: G Fernández-Esparrach, J Bernal, C Rodríguez De Miguel, D Gil, F Vilariño, H Córdova, C Sánchez-Montes, I Araujo, M López-Cerón, J Sánchez
Journal: Endoscopy (2015)

Introducción: La tasa de pólipos no detectados en la colonoscopia aumenta de forma significativa en los pólipos pequeños y planos.
The metformin effect on survival in Middle Eastern patients (pts) with type II diabetes (DM) and colorectal cancer (CRC).
Authors: Amal Al Omari, Hadeel Abdelkaleq, Maysa Al-Hussaini, Rim Turfa, Nour Awad, Manal Hassan, Chris R. Garrett
Journal: Journal of Clinical Oncology (2015)

e14541 Background: Epidemiologic data suggest that anti-DM medications may impact overall survival (OS) in CRC pts who have type 2 DM. Although type 2 DM and CRC are major health problems in the Middle East, little data exist on pts with both conditions from this region. Methods: Medical records from 1,898 CRC pts seen at King Hussein Cancer Center, between 1/1/2004 and 12/31/2012 were evaluated for prevalence of type 2 DM; those with both conditions were evaluated for anti-diabetic therapy and treatment outcomes (OS and progression-free survival (PFS)). Results: 355 type 2 DM CRC patients were identified (prevalence 18.7%); 25 pts were censored as their anti-DM medications were not known. Median age of 355 pts analyzed was 62 years (36-88), Male: Female ratio 1.5:1, non-metformin (n = 140, 42%), metformin only (n = 56, 17%), metformin + insulin (n = 15, 5%), metformin + another oral agent (n = 119, 36%). Metformin use increased over time (24% in 2004 to 79% in 2012). Adjusting for age, gender, body mass index, and stage, type 2 DM pts treated with metformin had a 40% improvement in OS (hazard ratio 0.6, 95% confidence interval (CI) 0.38-0.81). Conclusions: These data support previous findings that metformin use in CRC pts with type 2 DM is associated with superior PFS and OS. There was a statistically significant OS benefit in stage I-II and stage III pts, while the trend towards OS benefit in stage IV pts was not statistically significant. The benefit in PFS was statistically significant only in pts with stage III disease (see table). This study was supported by the King Hussein Cancer Center/MD Anderson Sister Institution Network Fund. OS median (months, 95% CI) Stage I-IV Stage I-II Stage III Stage IV Metformin Use 89 (64.1-113.9) Not reached Not reached 19 (12-26) Non-Metformin Use 42 (31.8-52.2) Not reached 50 (20-70) 16 (12-20) P value 0.001 0.046 0.012 0.059 PFS median (months, 95% CI) Stage I-V Stage I-II Stage IIII Stage IV Metformin Use 73 (44.35-101.65) Not reached 93 (NA) 15 (11.4-18.6) Non-Metformin Use 26 (13.8-38.2) 59 (NA) 35 (14-56) 14 (10-18) P value 0.001 0.193 0.015 0.3
THE IMPAIRED ENDOTHELIUM-DEPENDENT AND ENDOTHELIUM-INDEPENDENT SYSTEMIC ARTERIAL VASODILATORY RESERVE IN PULMONARY HYPERTENSION REGARDLESS OF THE CLINICAL GROUP
Authors: Muhittin Demirel, Ozgur Akbal, Aykun Hakgor, Fatih Yilmaz, Canan Elif Yildiz, Hacer Ceren Tokgoz Demircan, ibrahim Halil Tanboga, Sevim Turkday, Durmus Demir, Seda Tanyeri, Seda Tanyeri, Nihal Ozdemir, Cihangir Kaymaz
Journal: Journal of the American College of Cardiology (2017)